Acquired approvals
| Product | Current owner | Previous developer | Mode of acquisition | Indication |
|---|---|---|---|---|
| Sarclisa (isatuximab-irfc) | Sanofi | Immunogen | Licensed product | Third-line multiple myeloma |
| Vyepti (eptinezumab-jjmr) | Lundbeck (Valby, Denmark) | Alder BioPharmaceuticals | Bought Alder for $1.95 billion in 2019 | Migraine prevention |
| Tukysa (tucatinib) | Seagen | Array BioPharma via Cascadian Therapeutics | Bought Cascadian for $614 million in 2018 | Advanced HER2-positive breast cancer |
| Tepezza (teprotumumab-trbw) | Horizon Therapeutics | Genmab via River Vision and Roche | Bought River Vision for $145 million in 2017 | Thyroid eye disease |
| QWO (Clostridium histolyticum collagenase) | Endo | BioSpecifics Technologies | Bought BioSpecifics for $540 million in 2020 | Cellulite |
| Zeposia (ozanimod) | Bristol Myers Squibb | Celgene | Bought Celgene for $74 billion in 2019 | Relapsing multiple sclerosis |
| Byfavo (remimazolam) | Paion (Aachen, Germany) | GlaxoSmithKline via CeNeS Pharmaceuticals | Bought CeNeS for $22 million in 2008 | Procedural sedation |
| Xeglyze (abametapir) | Dr. Reddy’s Laboratories | HatchTech | Licensed product | Head lice infestation |
| Tecartus (brexucabtagene autoleucel) | Gilead Science | Kite Pharma | Bought Kite for $11.9 billion in 2017 | Advanced mantle cell lymphoma |